SLC22A1 and prostate carcinoma: For metformin, the highest number of its targets were associated with malignant neoplasm of the prostate (six genes) and breast carcinoma (seven genes: ABCB11; ABCC2; ABCC3; ABCC4; DHFR; DPP4; SLC22A1).